Skip to content
DataLookout
Menu

SKYSCRAPER-01NCT04294810

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 48 versions: 47 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 9, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 18 words
    • Primary endpoints: 4 to 8
    • Study sites: 134 to 132
    • Secondary endpoints: 7 to 28
    • Publications: 1 to 2
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Study sites: 132 to 134
    • Primary and study completion dates changed from estimate of Jan 31, 2026 to Dec 30, 2025
    v47
  3. Minor Study sites: 140 to 132
    • Primary and study completion dates: Dec 31, 2025 to Jan 31, 2026
    v46
  4. Minor Study sites: 141 to 140v45
  5. Notable Primary and study completion dates pushed to Dec 31, 2025
    • Study sites revised (141)
    v44
Show 41 earlier versionsHide 41 earlier versions
  1. Minor Primary completion date changed from estimate of Dec 1, 2025 to Sep 24, 2024v43
  2. Notable Primary and study completion dates: Feb 21, 2025 to Dec 1, 2025
    • Study sites: 154 to 141
    v42
  3. Minor Study sites revised (154)v41
  4. Minor Site details revised at 2 of 154 sitesv40
  5. Minor Study sites revised (154)v39
  6. Minor Study sites revised (154)v38
  7. Minor Study sites: 153 to 154v36
  8. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 660 to confirmed 620
    • Study sites: 180 to 153
    v35
  9. Minor Site details revised at 2 of 180 sitesv34
  10. Minor Site details revised at 4 of 180 sitesv33
  11. Minor Site details revised at 5 of 180 sitesv32
  12. Minor Site details revised at 4 of 180 sitesv31
  13. Minor Study sites: 179 to 180v30
  14. Minor Study sites: 177 to 179v29
  15. Minor Study sites: 176 to 177v28
  16. Minor Site details revised at 12 of 176 sitesv27
  17. Minor Site details revised at 1 of 176 sitesv26
  18. Minor Study sites revised (176)v25
  19. Minor Study sites revised (176)v24
  20. Notable Primary completion date: Aug 25, 2023 to Feb 21, 2025v23 Show 4 more changesShow less
    • Primary endpoints: 2 to 4
    • Enrollment target: 635 to 660
    • Secondary endpoints: 14 to 7
    • Site details revised at 5 of 176 sites
  21. Notable Primary completion date: Aug 25, 2022 to Aug 25, 2023
    • Study sites: 154 to 176
    v22
  22. Notable Eligibility criteria expanded, about 20 wordsv21 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Enrollment target: 560 to 635
    • Study sites: 153 to 154
    • Secondary endpoints: 16 to 14
  23. Minor Study sites: 173 to 153v20
  24. Minor Site details revised at 20 of 173 sitesv19
  25. Minor Study sites revised (173)v18
  26. Minor Site details revised at 10 of 173 sitesv17
  27. Minor Site details revised at 13 of 173 sitesv16
  28. Minor Study sites: 172 to 173v15
  29. Minor Study sites revised (172)v14
  30. Minor Site details revised at 15 of 172 sitesv13
  31. Minor Study sites revised (172)v12
  32. Minor Study sites revised (172)v11
  33. Notable Primary endpoints revised (2)v10 Show 4 more changesShow less
    • Eligibility criteria shortened, about 4 words
    • Enrollment target: 500 to 560
    • Secondary endpoints: 14 to 16
    • Site details revised at 17 of 172 sites
  34. Minor Study sites: 169 to 172v9
  35. Minor Study sites: 154 to 169v8
  36. Minor Study sites: 152 to 154v7
  37. Minor Study sites: 151 to 152v6
  38. Notable Eligibility criteria shortened, about 6 wordsv5 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Interventions: Atezolizumab (Drug), Matching Placebo (Other), Tiragolumab (Drug) to Atezolizumab (Drug), Matching Placebo (Drug), Tiragolumab (Drug)
    • Secondary endpoints revised (14)
    • Study sites revised (151)
  39. Minor Site details revised at 20 of 151 sitesv4
  40. Minor Site details revised at 4 of 151 sitesv3
  41. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 129 to 151
    • Start date changed from estimate of Feb 28, 2020 to Mar 4, 2020
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
Timeframe: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
Timeframe: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
Timeframe: From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
Timeframe: From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
Timeframe: Up to 65.1 months
China Cohort: Number of Participants With AEs
Timeframe: Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
Timeframe: Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
Timeframe: Up to 49.3 months

Secondary (28)

Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
Global Cohort: OS in the SAS
China Cohort: OS in the SAS
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
Show 23 moreShow less
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
China Cohort: Number of Participants With ADAs to Tiragolumab
Global Cohort: Number of Participants With ADAs to Atezolizumab
China Cohort: Number of Participants With ADAs to Atezolizumab

Arms and interventions

Tiragolumab + AtezolizumabExperimental

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Placebo + AtezolizumabPlacebo comparator

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Drugs: Atezolizumab, Tiragolumab, Matching Placebo

Sites

132 sites in 23 countries

China 18, Japan 12, South Korea 12, Italy 9, Taiwan 8, United States 8, Germany 7, Russia 6, Spain 6, Turkey (Türkiye) 6, Greece 4, Netherlands 4, Peru 4, Thailand 4, Australia 3, Austria 3, Hungary 3, Mexico 3, Poland 3, Switzerland 3, Brazil 2, Serbia 2, Ukraine 2